The Company will provide an update on its novel Doxorubicin containing Microneedle Array (D-MNA) treatment to non-invasively treat basal cell carcinoma of the skin (BCC) and development of Teverelix, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback